LVTX - LAVA Therapeutics GAAP EPS of -$0.48 beats by $0.02 revenue of $5.14M
2023-08-22 08:49:15 ET
More on LAVA Therapeutics
- Lava Therapeutics shelves hematology drug over competitive concerns
- LAVA Therapeutics initiated at buy at Wainwright on Gammabodies to treat cancer
- Lava Therapeutics begins dosing in phase 1/2a trial of LAVA-1207 to treat prostate cancer
- Lava Therapeutics jumps 9% after receiving FDA Orphan Drug tag for LAVA-051 in blood cancer
- Seeking Alpha’s Quant Rating on LAVA Therapeutics
- Earnings data for LAVA Therapeutics
For further details see:
LAVA Therapeutics GAAP EPS of -$0.48 beats by $0.02, revenue of $5.14M